$RIGL
RIGEL PHARMACEUTICALS INC

2024 Q1 Form 10-K Financial Statement

#000155837024002475 Filed on March 05, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $29.53M $35.79M $116.9M
YoY Change 13.29% -30.2% -2.79%
Cost Of Revenue $2.025M $3.790M $7.110M
YoY Change 107.27% 1008.19% 306.52%
Gross Profit $27.51M $32.00M $109.8M
YoY Change 9.63% -37.17% -7.36%
Gross Profit Margin 93.14% 89.41% 93.92%
Selling, General & Admin $28.45M $26.85M $105.7M
YoY Change 2.6% -16.54% -5.97%
% of Gross Profit 103.42% 83.9% 96.33%
Research & Development $6.026M $3.186M $24.52M
YoY Change -40.27% -79.26% -59.31%
% of Gross Profit 21.91% 9.96% 22.34%
Depreciation & Amortization $400.0K $288.0K $1.238M
YoY Change 12.04% 1.41% 24.05%
% of Gross Profit 1.45% 0.9% 1.13%
Operating Expenses $34.48M $30.04M $130.3M
YoY Change -8.84% -36.82% -24.58%
Operating Profit -$6.966M $1.966M -$20.49M
YoY Change -45.26% -42.16% -63.11%
Interest Expense $1.874M -$1.229M $6.872M
YoY Change 55.65% 81.27% 85.38%
% of Operating Profit -62.51%
Other Income/Expense, Net
YoY Change
Pretax Income -$11.78M $737.0K -$25.09M
YoY Change -12.99% -47.39% -57.16%
Income Tax
% Of Pretax Income
Net Earnings -$8.247M $737.0K -$25.09M
YoY Change -39.07% -47.39% -57.16%
Net Earnings / Revenue -27.92% 2.06% -21.47%
Basic Earnings Per Share -$0.05 -$0.14
Diluted Earnings Per Share -$0.05 $0.00 -$0.14
COMMON SHARES
Basic Shares Outstanding 175.4M 174.4M 174.0M
Diluted Shares Outstanding 175.2M 174.0M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $49.55M $56.93M $56.93M
YoY Change -15.53% -2.19% -2.19%
Cash & Equivalents $25.57M $32.79M $32.79M
Short-Term Investments $23.98M $24.15M $24.15M
Other Short-Term Assets $8.845M $6.261M $6.261M
YoY Change 12.43% -24.19% -24.19%
Inventory $6.579M $5.522M $5.522M
Prepaid Expenses
Receivables $27.51M $30.55M $30.55M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $92.49M $99.27M $99.27M
YoY Change -13.54% -14.35% -14.35%
LONG-TERM ASSETS
Property, Plant & Equipment $140.0K $165.0K $1.026M
YoY Change -52.38% -80.75% -63.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.318M $3.055M $3.055M
YoY Change 696.68% 377.34% 377.34%
Total Long-Term Assets $34.03M $17.96M $17.96M
YoY Change 104.53% -2.27% -2.27%
TOTAL ASSETS
Total Short-Term Assets $92.49M $99.27M $99.27M
Total Long-Term Assets $34.03M $17.96M $17.96M
Total Assets $126.5M $117.2M $117.2M
YoY Change 2.35% -12.7% -12.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.276M $7.142M $7.142M
YoY Change 47.36% -68.27% -68.27%
Accrued Expenses $15.52M $18.22M $18.22M
YoY Change -14.49% -24.71% -24.71%
Deferred Revenue $1.355M $1.355M
YoY Change -1.02% -1.02%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $14.78M $7.229M $7.229M
YoY Change
Total Short-Term Liabilities $73.20M $53.27M $53.27M
YoY Change 60.81% -18.32% -18.32%
LONG-TERM LIABILITIES
Long-Term Debt $44.91M $52.37M $52.37M
YoY Change -24.5% 32.76% 32.76%
Other Long-Term Liabilities $39.98M $39.94M $40.23M
YoY Change -4.95% -5.49% -6.95%
Total Long-Term Liabilities $39.98M $39.94M $92.60M
YoY Change -4.95% -5.49% 12.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $73.20M $53.27M $53.27M
Total Long-Term Liabilities $39.98M $39.94M $92.60M
Total Liabilities $158.2M $145.9M $145.9M
YoY Change 6.98% -1.37% -1.37%
SHAREHOLDERS EQUITY
Retained Earnings -$1.416B -$1.408B
YoY Change 1.42% 1.81%
Common Stock $1.384B $1.379B
YoY Change 0.9% 0.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$31.67M -$28.64M -$28.64M
YoY Change
Total Liabilities & Shareholders Equity $126.5M $117.2M $117.2M
YoY Change 2.35% -12.7% -12.7%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$8.247M $737.0K -$25.09M
YoY Change -39.07% -47.39% -57.16%
Depreciation, Depletion And Amortization $400.0K $288.0K $1.238M
YoY Change 12.04% 1.41% 24.05%
Cash From Operating Activities -$5.013M -$6.243M -$5.743M
YoY Change 23.05% -71.5% -92.21%
INVESTING ACTIVITIES
Capital Expenditures $138.0K $0.00 $15.00M
YoY Change -99.08% -100.0% 3233.33%
Acquisitions
YoY Change
Other Investing Activities $451.0K -$6.877M $10.70M
YoY Change -97.14% -136.83% -85.38%
Cash From Investing Activities $313.0K -$6.877M -$4.297M
YoY Change -59.72% -136.98% -105.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.512M 487.0K 18.37M
YoY Change -113.14% -123.23% 180.41%
NET CHANGE
Cash From Operating Activities -5.013M -6.243M -5.743M
Cash From Investing Activities 313.0K -6.877M -4.297M
Cash From Financing Activities -2.512M 487.0K 18.37M
Net Change In Cash -7.212M -12.63M 8.327M
YoY Change -145.57% 133.64% 49.52%
FREE CASH FLOW
Cash From Operating Activities -$5.013M -$6.243M -$5.743M
Capital Expenditures $138.0K $0.00 $15.00M
Free Cash Flow -$5.151M -$6.243M -$20.74M
YoY Change -72.99% -71.6% -72.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
174017000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
172406000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
170492000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001034842
CY2023 dei Entity Registrant Name
EntityRegistrantName
RIGEL PHARMACEUTICALS INC
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 rigl Net Sublease Income Expense
NetSubleaseIncomeExpense
CY2022 rigl Net Sublease Income Expense
NetSubleaseIncomeExpense
CY2021 rigl Net Sublease Income Expense
NetSubleaseIncomeExpense
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
173398645
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
174825610
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y5M1D
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y5M12D
CY2023 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2023 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
000-29889
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3248524
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
611 Gateway Boulevard, Suite 900,
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2023 dei City Area Code
CityAreaCode
650
CY2023 dei Local Phone Number
LocalPhoneNumber
624-1100
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $.001 per share
CY2023 dei Trading Symbol
TradingSymbol
RIGL
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Small Business
EntitySmallBusiness
false
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
222700000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
175377812
CY2023 dei Auditor Firm
AuditorFirmId
42
CY2023 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2023 dei Auditor Location
AuditorLocation
San Francisco, California
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32786000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24459000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
24147000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
33747000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
30550000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
40320000
CY2023Q4 us-gaap Inventory Net
InventoryNet
5522000
CY2022Q4 us-gaap Inventory Net
InventoryNet
9118000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6261000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8259000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
99266000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
115903000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
165000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
857000
CY2023Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
13878000
CY2022Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
14949000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
861000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1930000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3055000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
640000
CY2023Q4 us-gaap Assets
Assets
117225000
CY2022Q4 us-gaap Assets
Assets
134279000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7142000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
22508000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8676000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8866000
CY2023Q4 rigl Accrued Research And Development Liability Current
AccruedResearchAndDevelopmentLiabilityCurrent
3513000
CY2022Q4 rigl Accrued Research And Development Liability Current
AccruedResearchAndDevelopmentLiabilityCurrent
7708000
CY2023Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
15684000
CY2022Q4 us-gaap Contract With Customer Refund Liability Current
ContractWithCustomerRefundLiabilityCurrent
12145000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5334000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6485000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
692000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1133000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1355000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1369000
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
7229000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3642000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4997000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
53267000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
65211000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
285000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
972000
CY2023Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
52373000
CY2022Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
39448000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
39944000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
42264000
CY2023Q4 us-gaap Liabilities
Liabilities
145869000
CY2022Q4 us-gaap Liabilities
Liabilities
147895000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
174825610
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
173398645
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
175000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
174000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1378723000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1368822000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
8000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-153000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1407550000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1382459000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-28644000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-13616000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
117225000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
134279000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
116882000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
120242000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
149236000
CY2023 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7110000
CY2022 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1749000
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1083000
CY2023 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
24522000
CY2022 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
60272000
CY2021 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
65237000
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
105741000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
112451000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
91891000
CY2022 us-gaap Restructuring Charges
RestructuringCharges
1320000
CY2021 us-gaap Restructuring Charges
RestructuringCharges
3521000
CY2023 us-gaap Costs And Expenses
CostsAndExpenses
137373000
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
175792000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
161732000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-20491000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-55550000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-12496000
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
2272000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
684000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
47000
CY2023 us-gaap Interest Expense
InterestExpense
6872000
CY2022 us-gaap Interest Expense
InterestExpense
3707000
CY2021 us-gaap Interest Expense
InterestExpense
4860000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25091000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-58573000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17309000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
605000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-25091000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-58573000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-17914000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
174017000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
172406000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
170492000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25091000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-58573000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17914000
CY2023 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
161000
CY2022 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-51000
CY2021 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-98000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24930000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-58624000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18012000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
34026000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17914000
CY2021 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-98000
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
4775000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9585000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
30374000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-58573000
CY2022 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-51000
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2124000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12510000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-13616000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25091000
CY2023 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
161000
CY2023 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1049000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8853000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-28644000
CY2023 us-gaap Profit Loss
ProfitLoss
-25091000
CY2022 us-gaap Profit Loss
ProfitLoss
-58573000
CY2021 us-gaap Profit Loss
ProfitLoss
-17914000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
8806000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
12385000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
9486000
CY2023 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-266000
CY2022 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
138000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1238000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
998000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1162000
CY2022 rigl Noncash Interest Expense
NoncashInterestExpense
682000
CY2021 rigl Noncash Interest Expense
NoncashInterestExpense
3139000
CY2023 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
479000
CY2022 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
63000
CY2021 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-287000
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-9770000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
24848000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-501000
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1172000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2377000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4875000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1998000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
847000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-6633000
CY2023 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-56000
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-334000
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
150000
CY2023 rigl Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
1069000
CY2022 rigl Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
7773000
CY2021 rigl Increase Decrease Right Of Use Assets
IncreaseDecreaseRightOfUseAssets
8192000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-366000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3788000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
41000
CY2023 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-190000
CY2022 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1824000
CY2021 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1098000
CY2023 rigl Increase Decrease In Accrued Research And Development Liability
IncreaseDecreaseInAccruedResearchAndDevelopmentLiability
-4195000
CY2022 rigl Increase Decrease In Accrued Research And Development Liability
IncreaseDecreaseInAccruedResearchAndDevelopmentLiability
-2676000
CY2021 rigl Increase Decrease In Accrued Research And Development Liability
IncreaseDecreaseInAccruedResearchAndDevelopmentLiability
5495000
CY2023 rigl Revenue Reserves And Refund Liability
RevenueReservesAndRefundLiability
3539000
CY2022 rigl Revenue Reserves And Refund Liability
RevenueReservesAndRefundLiability
4230000
CY2021 rigl Revenue Reserves And Refund Liability
RevenueReservesAndRefundLiability
1850000
CY2023 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1151000
CY2022 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1709000
CY2021 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-24000
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1128000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-8546000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-8621000
CY2023 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-14000
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1227000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-422000
CY2023 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1043000
CY2022 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-4538000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5743000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-73758000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5878000
CY2023 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
41650000
CY2022 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
101228000
CY2021 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
62050000
CY2023 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
31206000
CY2022 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
28894000
CY2021 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
141459000
CY2023 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
15000000
CY2023 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
259000
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
893000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
450000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
627000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4297000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
72777000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-80036000
CY2023 us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
19950000
CY2022 us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
19542000
CY2023 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1049000
CY2022 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2124000
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
4775000
CY2021 rigl Cost Share Advance From Collaboration Partner
CostShareAdvanceFromCollaborationPartner
57900000
CY2023 rigl Payment Of Cost Share To Collaboration Partner
PaymentOfCostShareToCollaborationPartner
2632000
CY2022 rigl Payment Of Cost Share To Collaboration Partner
PaymentOfCostShareToCollaborationPartner
15116000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18367000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6550000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
62675000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
8327000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
5569000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-11483000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24459000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18890000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30373000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32786000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24459000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18890000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
5848000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
2495000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
1500000
CY2022 rigl Intangible Assets Incurred But Not Yet Paid
IntangibleAssetsIncurredButNotYetPaid
15000000
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
56900000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Estimates </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with US GAAP requires management to make certain judgments, estimates and assumptions that could affect the reported <span style="background:#ffffff;">amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Critical accounting estimates </span>and assumptions made by management include those relating to estimates around our product sales allowances and discounts; estimates around accounting for collaboration arrangements; and<span style="color:#ff0000;"> </span>estimates around research and development accruals. Other accounting estimates also include but not limited to allowance for credit losses, inventory reserves, estimated general accruals, valuation of our stock option awards and probability of achievement of corporate performance-based milestones for our performance-based stock option awards, valuation allowance on deferred tax asset, estimated useful lives of long-lived assets, and any potential impairment loss.<span style="background:#ffffff;"> We base our estimates and assumptions on historical experience and on various other assumptions we believe to be applicable, and evaluate them on an ongoing basis to ensure they remain reasonable under current conditions. Actual results could differ significantly from those estimates, which could have a material impact on our business, results of operations, and financial condition.</span><span style="background:#ffffff;"> </span></p>
CY2023 rigl Share Based Compensation Arrangement By Share Based Payment Award Options Number Of Homogenous Groups For Determining Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfHomogenousGroupsForDeterminingFairValue
3
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q4 rigl Customer Allowance For Prompt Payment Discounts
CustomerAllowanceForPromptPaymentDiscounts
136000
CY2021Q4 rigl Customer Allowance For Prompt Payment Discounts
CustomerAllowanceForPromptPaymentDiscounts
106000
CY2020Q4 rigl Customer Allowance For Prompt Payment Discounts
CustomerAllowanceForPromptPaymentDiscounts
171000
CY2023 rigl Customer Allowance For Prompt Payment Discounts Period Increase
CustomerAllowanceForPromptPaymentDiscountsPeriodIncrease
686000
CY2022 rigl Customer Allowance For Prompt Payment Discounts Period Increase
CustomerAllowanceForPromptPaymentDiscountsPeriodIncrease
557000
CY2021 rigl Customer Allowance For Prompt Payment Discounts Period Increase
CustomerAllowanceForPromptPaymentDiscountsPeriodIncrease
609000
CY2023 rigl Customer Allowance For Prompt Payment Discounts Period Decrease
CustomerAllowanceForPromptPaymentDiscountsPeriodDecrease
642000
CY2022 rigl Customer Allowance For Prompt Payment Discounts Period Decrease
CustomerAllowanceForPromptPaymentDiscountsPeriodDecrease
527000
CY2021 rigl Customer Allowance For Prompt Payment Discounts Period Decrease
CustomerAllowanceForPromptPaymentDiscountsPeriodDecrease
674000
CY2023Q4 rigl Customer Allowance For Prompt Payment Discounts
CustomerAllowanceForPromptPaymentDiscounts
180000
CY2022Q4 rigl Customer Allowance For Prompt Payment Discounts
CustomerAllowanceForPromptPaymentDiscounts
136000
CY2021Q4 rigl Customer Allowance For Prompt Payment Discounts
CustomerAllowanceForPromptPaymentDiscounts
106000
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Concentration of Credit Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject us to a concentration of credit risk are primarily cash, investment in debt securities and accounts receivable. All of our cash and investment in debt securities are maintained with financial institutions that management believes are creditworthy. By policy, we limit the concentration of credit risk by diversifying our investments among a variety of high credit-quality issuers. Due to the short-term nature of these investments, we believe we do not have a material exposure to credit risk arising from our investments. We have not historically experienced any significant credit losses related to these financial instruments and do not believe that we are exposed to any significant credit risk related to these instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Concentration of credit risk with respect to our accounts receivable is limited due to our small number of customers. Our accounts receivable consists mostly of outstanding invoices from our sale of our product to our specialty distributors. Accounts receivable may also include outstanding invoices from our collaboration partners with respect to the related sponsored research and license agreements and government contracts. As of December 31, 2023, 87% of our accounts receivable consisted of outstanding invoices from our specialty distributors, and the remaining 13% are outstanding invoices from our collaboration partners, mainly Grifols. As of December 31, 2022, 49% of our accounts receivable are outstanding invoices from our specialty distributors, and the remaining 51% are outstanding invoices from our collaboration partners, mainly Kissei which include a $20.0 million regulatory milestone receivable that was subsequently collected in January 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">See “Note 3 - Revenues” for summary of revenues from each of our customers who individually accounted for 10% or more of the total net product sales and revenues from collaborations. </p>
CY2023 us-gaap Advertising Expense
AdvertisingExpense
3100000
CY2022 us-gaap Advertising Expense
AdvertisingExpense
2700000
CY2021 us-gaap Advertising Expense
AdvertisingExpense
2300000
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
35985000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
35800000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
30235000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
116882000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
120242000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
149236000
CY2023 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
41500000
CY2022 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
30900000
CY2021 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
16800000
CY2022Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
12145000
CY2023 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
41498000
CY2023 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
37959000
CY2023Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
15684000
CY2021Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
7915000
CY2022 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
30903000
CY2022 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
26673000
CY2022Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
12145000
CY2021 rigl Collaborative Arrangement Upfront Fee Received
CollaborativeArrangementUpfrontFeeReceived
125000000.0
CY2023 rigl Right To Opt Out Of Agreement Number Of Periods
RightToOptOutOfAgreementNumberOfPeriods
2
CY2023 us-gaap Accretion Expense
AccretionExpense
700000
CY2022 us-gaap Accretion Expense
AccretionExpense
2800000
CY2022Q4 rigl Financing Liability Including Interest Expense Accretion
FinancingLiabilityIncludingInterestExpenseAccretion
46200000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8806000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12385000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9486000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
500000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
1400000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
400000
CY2023 rigl Number Of Active Equity Plans
NumberOfActiveEquityPlans
2
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
10600000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
4609000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
4555000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1876000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
2659000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1508000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1904000
CY2023Q4 rigl Inventory And Inventory Reported As Other Assets
InventoryAndInventoryReportedAsOtherAssets
7993000
CY2022Q4 rigl Inventory And Inventory Reported As Other Assets
InventoryAndInventoryReportedAsOtherAssets
9118000
CY2023Q4 us-gaap Inventory Net
InventoryNet
5522000
CY2022Q4 us-gaap Inventory Net
InventoryNet
9118000
CY2023Q4 rigl Inventory Reported As Other Assets
InventoryReportedAsOtherAssets
2471000
CY2023Q4 rigl Inventory And Inventory Reported As Other Assets
InventoryAndInventoryReportedAsOtherAssets
7993000
CY2022Q4 rigl Inventory And Inventory Reported As Other Assets
InventoryAndInventoryReportedAsOtherAssets
9118000
CY2023Q4 us-gaap Advances On Inventory Purchases
AdvancesOnInventoryPurchases
0
CY2022Q4 us-gaap Advances On Inventory Purchases
AdvancesOnInventoryPurchases
800000
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
56933000
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
58206000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32786000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24459000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
24147000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
33747000
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
56933000
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
58206000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
38993000
CY2023Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
39001000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
47940000
CY2022Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
47787000
CY2023 rigl Cash Equivalents And Available For Sale Securities Weighted Average Maturity Period
CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P82D
CY2022 rigl Cash Equivalents And Available For Sale Securities Weighted Average Maturity Period
CashEquivalentsAndAvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P89D
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
10
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
10541000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
7000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1869000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11664000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1704000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10807000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
165000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
857000
CY2023 rigl Depreciation And Amortization Expense
DepreciationAndAmortizationExpense
200000
CY2022 rigl Depreciation And Amortization Expense
DepreciationAndAmortizationExpense
900000
CY2021 rigl Depreciation And Amortization Expense
DepreciationAndAmortizationExpense
1200000
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
15000000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
15000000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1122000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
51000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
13878000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
14949000
CY2023Q4 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P14Y
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1100000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1071000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1071000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1071000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1071000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
1071000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
8523000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
13878000
CY2023Q4 rigl Accrued Commercial Expenses Current
AccruedCommercialExpensesCurrent
1852000
CY2022Q4 rigl Accrued Commercial Expenses Current
AccruedCommercialExpensesCurrent
3144000
CY2023Q4 rigl Accrued Other Expenses Current
AccruedOtherExpensesCurrent
3482000
CY2022Q4 rigl Accrued Other Expenses Current
AccruedOtherExpensesCurrent
3341000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5334000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6485000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
60000000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
40000000
CY2023Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
398000
CY2022Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
552000
CY2023Q4 rigl Debt Principal Outstanding Net Of Unamortized Debt Issuance Costs
DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts
59602000
CY2022Q4 rigl Debt Principal Outstanding Net Of Unamortized Debt Issuance Costs
DebtPrincipalOutstandingNetOfUnamortizedDebtIssuanceCosts
39448000
CY2023Q4 us-gaap Loans Payable Current
LoansPayableCurrent
7229000
CY2023Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
52373000
CY2022Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
39448000
CY2023Q4 us-gaap Loans Payable
LoansPayable
59602000
CY2022Q4 us-gaap Loans Payable
LoansPayable
39448000
CY2023 us-gaap Line Of Credit Facility Increase Accrued Interest
LineOfCreditFacilityIncreaseAccruedInterest
1500000
CY2022 us-gaap Line Of Credit Facility Increase Accrued Interest
LineOfCreditFacilityIncreaseAccruedInterest
800000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
7500000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
30000000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
22500000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
60000000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
1109000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
5470000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
5360000
CY2023 us-gaap Variable Lease Cost
VariableLeaseCost
134000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
818000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
910000
CY2023 us-gaap Lease Cost
LeaseCost
1243000
CY2022 us-gaap Lease Cost
LeaseCost
6288000
CY2021 us-gaap Lease Cost
LeaseCost
6270000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
1534000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
10485000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
10082000
CY2023 rigl Fixed Sublease Expense
FixedSubleaseExpense
365000
CY2022 rigl Fixed Sublease Expense
FixedSubleaseExpense
4381000
CY2021 rigl Fixed Sublease Expense
FixedSubleaseExpense
4381000
CY2023 rigl Variable Sublease Expense
VariableSubleaseExpense
77000
CY2022 rigl Variable Sublease Expense
VariableSubleaseExpense
911000
CY2021 rigl Variable Sublease Expense
VariableSubleaseExpense
917000
CY2023 us-gaap Sublease Income
SubleaseIncome
442000
CY2022 us-gaap Sublease Income
SubleaseIncome
5292000
CY2021 us-gaap Sublease Income
SubleaseIncome
5298000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
739000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
301000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1040000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
600000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
229967000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
230373000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
62457000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
68646000
CY2023Q4 rigl Deferred Tax Assets Capitalized Research And Development Costs
DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
21017000
CY2022Q4 rigl Deferred Tax Assets Capitalized Research And Development Costs
DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
15680000
CY2023Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
11223000
CY2022Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
11234000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
10365000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
9620000
CY2023Q4 rigl Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
244000
CY2022Q4 rigl Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
504000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3654000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2494000
CY2023Q4 rigl Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
215000
CY2022Q4 rigl Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
461000
CY2023Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
81000
CY2022Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
439000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
338631000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
337651000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
338631000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
337651000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.001
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.000
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.028
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.139
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.202
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.275
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.053
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.025
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.056
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.002
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.026
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.140
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.015
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.010
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.027
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.001
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.036
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1000000.0
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
15300000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
6600000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9426000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9186000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
8901000
CY2023 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
843000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
89000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
240000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
285000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
8672000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9426000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9186000
CY2023 rigl Unrecognized Tax Benefits Decreases Resulting From Evaluation Of Prior Orphan Drug Credits
UnrecognizedTaxBenefitsDecreasesResultingFromEvaluationOfPriorOrphanDrugCredits
4700000
CY2022 us-gaap Restructuring Charges
RestructuringCharges
1300000
CY2021 us-gaap Restructuring Charges
RestructuringCharges
3500000

Files In Submission

Name View Source Status
0001558370-24-002475-index-headers.html Edgar Link pending
0001558370-24-002475-index.html Edgar Link pending
0001558370-24-002475.txt Edgar Link pending
0001558370-24-002475-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rigl-20231231.xsd Edgar Link pending
rigl-20231231x10k.htm Edgar Link pending
rigl-20231231x10k003.jpg Edgar Link pending
rigl-20231231x10k004.jpg Edgar Link pending
rigl-20231231xex10d9.htm Edgar Link pending
rigl-20231231xex23d1.htm Edgar Link pending
rigl-20231231xex31d1.htm Edgar Link pending
rigl-20231231xex31d2.htm Edgar Link pending
rigl-20231231xex32d1.htm Edgar Link pending
rigl-20231231xex97.htm Edgar Link pending
Show.js Edgar Link pending
rigl-20231231_cal.xml Edgar Link unprocessable
rigl-20231231_def.xml Edgar Link unprocessable
rigl-20231231_lab.xml Edgar Link unprocessable
rigl-20231231_pre.xml Edgar Link unprocessable
rigl-20231231x10k_htm.xml Edgar Link completed